hydroxychloroquine has been researched along with Break-Bone Fever in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is an antimalarial drug also used in treating autoimmune diseases." | 5.42 | Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. ( Chang, TH; Chen, JJ; Chen, SR; Huang, NC; Kubota, T; Lin, YL; Lin, YS; Lu, RW; Matsuoka, M; Tsai, WL; Wang, LF; Yang, CS; Yu, CY, 2015) |
| "Hydroxychloroquine (HCQ) is an antimalarial drug also used in treating autoimmune diseases." | 1.42 | Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. ( Chang, TH; Chen, JJ; Chen, SR; Huang, NC; Kubota, T; Lin, YL; Lin, YS; Lu, RW; Matsuoka, M; Tsai, WL; Wang, LF; Yang, CS; Yu, CY, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behnam, MA | 1 |
| Nitsche, C | 1 |
| Boldescu, V | 1 |
| Klein, CD | 1 |
| Wang, LF | 1 |
| Lin, YS | 1 |
| Huang, NC | 1 |
| Yu, CY | 1 |
| Tsai, WL | 1 |
| Chen, JJ | 1 |
| Kubota, T | 1 |
| Matsuoka, M | 1 |
| Chen, SR | 1 |
| Yang, CS | 1 |
| Lu, RW | 1 |
| Lin, YL | 1 |
| Chang, TH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydroxychloroquine and Break-Bone Fever
| Article | Year |
|---|---|
The Medicinal Chemistry of Dengue Virus.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Dengue; Dengue Virus; Humans; Molecular Conformation; S | 2016 |
1 other study available for hydroxychloroquine and Break-Bone Fever
| Article | Year |
|---|---|
Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line; Dengue; Dengue Virus; Epithelial Cells; Ge | 2015 |